CA3191030A1 - Treatment of sepsis with pcsk9 and ldlr modulators - Google Patents
Treatment of sepsis with pcsk9 and ldlr modulatorsInfo
- Publication number
- CA3191030A1 CA3191030A1 CA3191030A CA3191030A CA3191030A1 CA 3191030 A1 CA3191030 A1 CA 3191030A1 CA 3191030 A CA3191030 A CA 3191030A CA 3191030 A CA3191030 A CA 3191030A CA 3191030 A1 CA3191030 A1 CA 3191030A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- nucleic acid
- acid molecule
- pcsk9
- complement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063069789P | 2020-08-25 | 2020-08-25 | |
| US63/069,789 | 2020-08-25 | ||
| PCT/US2021/047502 WO2022046873A1 (en) | 2020-08-25 | 2021-08-25 | Treatment of sepsis with pcsk9 and ldlr modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3191030A1 true CA3191030A1 (en) | 2022-03-03 |
Family
ID=77775030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3191030A Pending CA3191030A1 (en) | 2020-08-25 | 2021-08-25 | Treatment of sepsis with pcsk9 and ldlr modulators |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12378557B2 (https=) |
| EP (1) | EP4204563A1 (https=) |
| JP (2) | JP2023539742A (https=) |
| KR (1) | KR20230057410A (https=) |
| CN (1) | CN116171161A (https=) |
| AU (1) | AU2021335200A1 (https=) |
| CA (1) | CA3191030A1 (https=) |
| IL (1) | IL300439A (https=) |
| MX (1) | MX2023001912A (https=) |
| WO (1) | WO2022046873A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2634837A (en) | 2022-06-07 | 2025-04-23 | Scribe Therapeutics Inc | Compositions and methods for the targeting of PCSK9 |
| CN119716057B (zh) * | 2024-12-10 | 2025-07-15 | 中国人民解放军总医院 | Pcsk6在诊断脓毒症中的应用 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1471152A1 (en) | 2003-04-25 | 2004-10-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mutations in the human PCSK9 gene associated to hypercholesterolemia |
| KR100985090B1 (ko) | 2008-05-23 | 2010-10-04 | 한국과학기술연구원 | 크라이센 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법 |
| JP5703218B2 (ja) | 2008-08-14 | 2015-04-15 | ネステク ソシエテ アノニム | 満腹感、脂質代謝及び脂肪利用に影響を及ぼすための組成物及び方法 |
| EP2488663A4 (en) | 2009-10-16 | 2012-09-05 | Genetics Invest Pty Ltd | SENSITIVITY TO MACRONUTRIENT |
| WO2012048414A1 (en) | 2010-10-12 | 2012-04-19 | Mcmaster University | A method of regulating plasma lipoproteins |
| WO2013043041A2 (en) | 2011-09-21 | 2013-03-28 | Infovalley® Group Of Companies | Methods and compositions for diagnosing familial hypercholesterolemia |
| US20150140005A1 (en) * | 2012-05-17 | 2015-05-21 | Cyon Therapeutics Inc. | Methods and Uses for Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors |
| WO2014028946A2 (en) | 2012-08-17 | 2014-02-20 | The Broad Institute, Inc. | Modulators of hepatic lipoprotein metabolism |
| TWI682780B (zh) | 2013-05-30 | 2020-01-21 | 美商再生元醫藥公司 | 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途 |
| EP3052521A1 (en) * | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| WO2015073709A2 (en) | 2013-11-14 | 2015-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Detection of atherosclerotic cardiovascular disease risk and heart failure risk |
| WO2015073710A2 (en) | 2013-11-14 | 2015-05-21 | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES | Detection of atherosclerotic cardiovascular disease risk and myocardial infarction risk |
| US9023359B1 (en) | 2014-07-15 | 2015-05-05 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
| US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
| WO2015092393A2 (en) | 2013-12-17 | 2015-06-25 | Kymab Limited | Human targets |
| US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
| US9051378B1 (en) | 2014-07-15 | 2015-06-09 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
| US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US9045548B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
| US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
| CA2947127A1 (en) | 2014-05-02 | 2015-11-19 | Cerenis Therapeutics Holding Sa | Hdl therapy markers |
| EP4328245A3 (en) | 2014-07-15 | 2024-06-05 | Kymab Ltd. | Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations |
| US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
| US9150660B1 (en) | 2014-07-15 | 2015-10-06 | Kymab Limited | Precision Medicine by targeting human NAV1.8 variants for treatment of pain |
| WO2016023916A1 (en) | 2014-08-12 | 2016-02-18 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
| WO2016071701A1 (en) | 2014-11-07 | 2016-05-12 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
| NL2014136B1 (en) | 2015-01-14 | 2017-01-27 | Stichting Katholieke Univ | Annexin A2 SNP and von Willebrand Disease. |
| US10265379B2 (en) | 2015-09-16 | 2019-04-23 | Annabelle Rodriguez Oquendo | Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases |
| WO2017218798A1 (en) | 2016-06-15 | 2017-12-21 | Boston Heart Diagnostics | Systems and methods for diagnosing familial hypercholesterolemia |
| ES2871783T3 (es) * | 2016-09-20 | 2021-11-02 | Univ Aarhus | Compuestos para el tratamiento de trastornos del metabolismo de las lipoproteínas |
| US10337070B2 (en) | 2017-01-12 | 2019-07-02 | Cardioforecast Ltd. | Methods and kits for treating cardiovascular disease |
| US20190345557A1 (en) | 2017-07-12 | 2019-11-14 | The General Hospital Corporation | Atrial fibrillation polygenic risk score |
| US20190017119A1 (en) | 2017-07-12 | 2019-01-17 | The General Hospital Corporation | Genetic Risk Predictor |
| US20190341125A1 (en) | 2017-07-12 | 2019-11-07 | The General Hospital Corporation | Inflammatory bowel disease polygenic risk score |
| US20190330698A1 (en) | 2017-07-12 | 2019-10-31 | The General Hospital Corporation | Diabetes polygenic risk score |
| US20190345566A1 (en) | 2017-07-12 | 2019-11-14 | The General Hospital Corporation | Cancer polygenic risk score |
| US11680296B2 (en) | 2017-10-16 | 2023-06-20 | Massachusetts Institute Of Technology | Mycobacterium tuberculosis host-pathogen interaction |
| WO2019199684A1 (en) | 2018-04-09 | 2019-10-17 | The Regents Of The University Of Michigan | Methods and systems for biocellular marker detection and diagnosis using a microfluidic profiling device |
| MX2020013994A (es) | 2018-06-22 | 2021-05-27 | Bluestar Genomics Inc | Análisis de hidroximetilación de muestras de ácido nucleico sin células para asignación de tejido de origen, y métodos relacionados de uso. |
| US20210285050A1 (en) | 2018-07-06 | 2021-09-16 | United States Government As Represented By The Department Of Veterans Affairs | Pde3b variants |
| WO2020010186A1 (en) * | 2018-07-06 | 2020-01-09 | Derek Klarin | Pcsk9 variants |
| JP2022507958A (ja) * | 2018-11-27 | 2022-01-18 | ノバルティス アーゲー | 代謝障害の治療用のプロタンパク質転換酵素サブチリシン／ケキシン９型（ｐｃｓｋ９）阻害薬としての環状四量体化合物 |
| EP3969620B1 (en) | 2019-05-17 | 2025-06-25 | Regeneron Pharmaceuticals, Inc. | Genome-based methods for reducing cardiovascular risk |
| CN113874020A (zh) | 2019-05-22 | 2021-12-31 | 基诺富公司 | 使用曲美替尼和标志物治疗神经退化性疾病的给药方法和剂量方案 |
| US20200368239A1 (en) | 2019-05-22 | 2020-11-26 | Genuv Inc. | Treatment of amyotrophic lateral sclerosis using trametinib |
| WO2021058597A1 (en) | 2019-09-24 | 2021-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of determining whether a subject is at risk of developing arterial plaques |
| US20210113536A1 (en) | 2019-10-21 | 2021-04-22 | United States Government as Represented by the Department of Veteran Affairs | Methods and compositions for detecting and treating venous thromboembolism |
-
2021
- 2021-08-25 CN CN202180062771.1A patent/CN116171161A/zh active Pending
- 2021-08-25 JP JP2023513460A patent/JP2023539742A/ja active Pending
- 2021-08-25 WO PCT/US2021/047502 patent/WO2022046873A1/en not_active Ceased
- 2021-08-25 AU AU2021335200A patent/AU2021335200A1/en not_active Withdrawn
- 2021-08-25 KR KR1020237009863A patent/KR20230057410A/ko not_active Withdrawn
- 2021-08-25 US US17/411,460 patent/US12378557B2/en active Active
- 2021-08-25 IL IL300439A patent/IL300439A/en unknown
- 2021-08-25 CA CA3191030A patent/CA3191030A1/en active Pending
- 2021-08-25 MX MX2023001912A patent/MX2023001912A/es unknown
- 2021-08-25 EP EP21770398.2A patent/EP4204563A1/en not_active Withdrawn
-
2025
- 2025-07-01 US US19/256,467 patent/US20260078378A1/en active Pending
- 2025-09-19 JP JP2025155627A patent/JP2026004359A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL300439A (en) | 2023-04-01 |
| WO2022046873A1 (en) | 2022-03-03 |
| KR20230057410A (ko) | 2023-04-28 |
| US20260078378A1 (en) | 2026-03-19 |
| AU2021335200A9 (en) | 2024-10-03 |
| JP2023539742A (ja) | 2023-09-19 |
| EP4204563A1 (en) | 2023-07-05 |
| JP2026004359A (ja) | 2026-01-14 |
| US12378557B2 (en) | 2025-08-05 |
| US20220064652A1 (en) | 2022-03-03 |
| AU2021335200A1 (en) | 2023-04-27 |
| CN116171161A (zh) | 2023-05-26 |
| MX2023001912A (es) | 2023-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260078378A1 (en) | Treatment Of Sepsis With PCSK9 And LDLR Modulators | |
| US20240102013A1 (en) | Treatment Of Ophthalmic Conditions With Son of Sevenless 2 (SOS2) Inhibitors | |
| CA3218042A1 (en) | Treatment of cerebrovascular disease with neurogenic locus notch homolog protein 3 (notch3) agents | |
| US20230192864A1 (en) | Treatment Of Lung Conditions With Integrin Subunit Alpha 1 (ITGA1) Inhibitors | |
| US20230034093A1 (en) | Treatment Of Cognitive Impairment With Alpha-N-Acetylgalactosaminide Alpha-2,6-Sialyltransferase 5 (ST6GALNAC5) Inhibitors | |
| AU2022307083A1 (en) | Methods of treating skin cancer with carboxypeptidase vitellogenic like (cpvl) inhibitors | |
| WO2022187183A1 (en) | Treatment of liver disease with ring finger protein 213 (rnf213) inhibitors | |
| EP4416286A1 (en) | Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (erap1) inhibitors | |
| EP4363583A1 (en) | Methods of treating asthma with solute carrier family 27 member 3 (slc27a3) inhibitors | |
| WO2023278694A1 (en) | Treatment of hypertension with solute carrier family 9 isoform a3 regulatory factor 2 (slc9a3r2) inhibitors | |
| CA3232251A1 (en) | Treatment of glaucoma with rho guanine nucleotide exchange factor 12 (arhgef12) inhibitors | |
| CN118265529A (zh) | 使用camp应答元件结合蛋白3样3(creb3l3)抑制剂的肝病治疗 | |
| CN118613584A (zh) | 使用内质网氨基肽酶1(erap1)抑制剂治疗葡萄膜炎 | |
| CA3141309A1 (en) | Synaptojanin 2 (synj2) variants and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240726 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241217 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241217 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250724 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250820 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250820 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250820 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250820 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250820 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250828 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250903 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250908 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250908 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250908 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250908 |